Understanding how immune responses cause heart and lung problems after cancer treatments.
Autoimmunity in Cardiopulmonary Toxicities from Radiotherapy andImmunotherapy
This study is looking at how certain immune responses can cause serious heart and lung problems in lung cancer patients who are getting radiation therapy and a specific type of immunotherapy, with the hope of finding ways to prevent these side effects and improve treatment outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10643954 on NIH RePORTER |
What this research studies
This research investigates the immune mechanisms that lead to serious heart and lung toxicities in patients receiving thoracic radiotherapy and PD-1 blocking immunotherapy. By analyzing blood samples from lung cancer patients and using mouse models, the study aims to identify biological markers and therapeutic targets that could help prevent these life-threatening side effects. The research team will focus on the role of specific immune responses, particularly involving B-cells and the cytokine IL-17A, in causing these toxicities. The ultimate goal is to develop early diagnostic tests and interventions to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients undergoing combined radiotherapy and immunotherapy.
Not a fit: Patients who are not undergoing thoracic radiotherapy or PD-1 blocking immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tools and treatments that reduce the risk of severe cardiopulmonary toxicities in cancer patients.
How similar studies have performed: Previous studies have shown that understanding immune responses can lead to significant advancements in managing treatment-related toxicities, suggesting potential success for this approach.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Lu, Bo — University of Missouri-Columbia
- Study coordinator: Lu, Bo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.